BA
CERE

Bellwether Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Bellwether Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,197
Closed -$507K – 623
2021
Q3 		$507K Buy
+17,197
New +$483K 0.17% 102

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bellwether Advisors's CERE Position: Q4 2021 in Review

Bellwether Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2021, closing a stake of 17,197 shares — an estimated $507K sold.

Bellwether Advisors first reported a position in CERE in Q3 2021 and held it in 1 quarter. The position peaked at $507K in Q3 2021. 107 funds tracked by Wall St. Rank hold CERE as of Q4 2021.

  • Bellwether Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Bellwether Advisors sold 17,197 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2021, an estimated $507K.
  • Bellwether Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Bellwether Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $507K in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2021.

Based on Bellwether Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.